Indaptus Therapeutics

INDP

Market cap $353M

INDP Hedge Fund Activity: Q1 2026 in Review

6 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2026, worth a combined $129K — up 37% from $93.7K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new INDP positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $83.7K. The largest seller was UBS Group, exiting entirely with an estimated $84.4K sold.

• 6 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2026, up from 4 in Q4 2025.
• Funds reported $129K of Indaptus Therapeutics stock for Q1 2026, up 37% quarter-over-quarter.
• 4 funds opened new Indaptus Therapeutics positions in Q1 2026 and 2 closed out, a net change of +2 holders.
• The largest Indaptus Therapeutics buyer in Q1 2026 was Citadel Advisors, an estimated $83.7K added.
• The largest Indaptus Therapeutics seller in Q1 2026 was UBS Group, an estimated $84.4K sold.

Based on aggregated 13F filings for Q1 2026.